Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MGMT | P16455 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18750482 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL21090258 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL30180781 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25345611 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25495530 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL24629752 | 1.00 | CRBN (0.32) | CRBNMGMTABCG2 | |
| SCHEMBL25495560 | 0.98 | CRBN (0.30) | CRBN | |
| SCHEMBL25976305 | 0.96 | CRBN (0.31) | CRBN | |
| SCHEMBL25496794 | 0.95 | TTR (0.33) | CRBN | |
| SCHEMBL24894500 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551230-A2 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Dyne Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119630407-A | Muscle targeting complexes and their use for the treatment of facial shoulder humerus muscular dystrophy | 达因疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024011135-A2 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4271478-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Dyne Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116916938-A | Muscle targeting complexes and their use for the treatment of facial shoulder humerus muscular dystrophy | 达因疗法公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230044430-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | KRANTZ ALEXANDER (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115315263-A | Cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11400165-B2 | Composition and method for modifying polypeptides | ADVANCED PROTEOME THERAPEUTICS INC. (US) | 2022-08-02 | — | — | US | disclosed |
| WO-2022147207-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | ADVANCED PROTEOME THERAPEUTICS INC. | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044430-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | PTMS, SRMS, ACP1 | CRBN 7/4885MGMT 2883/4885ABCG2 1401/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | CRBN 3454/4885MGMT 2296/4885ABCG2 675/4885 |
| US-11400165-B2 | Composition and method for modifying polypeptides | PTMS, SRMS, ACP1 | CRBN 7/4885MGMT 2883/4885ABCG2 1401/4885 |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | PTMS, SRMS, ACP1 | CRBN 7/4885MGMT 2883/4885ABCG2 1401/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | CRBN 2889/4885MGMT 4124/4885ABCG2 337/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | CRBN 1518/4885MGMT 2581/4885ABCG2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.